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PreviewsWhy did it take so long for monogenic
forms of autoimmunity to gain recogni-
tion?Mendelian traits have often been ne-
glected because of their supposed rarity,
with the perpetual comparison of com-
plex/common versus Mendelian/rare
diseases. This dates back to the turn of
the 20th century, when biometricians
attacked Mendelism. Because most phe-
notypes do not segregate as Mendelian
traits, it was believed that the core Men-
delian principles of genetics were also
wrong. This controversy is not yet entirely
settled, and the term Mendelian is still
used in two ways, referring to monogenic
traits (not necessarily fully penetrant) or
to fully penetrant traits (not necessarily
monogenic). Moreover, there is obviously
no pure Mendelian trait, both fully mono-
genic and fully penetrant, as there is no
single-gene organism defining a single-
organism population. Even cystic fibrosis
and sickle-cell disease are not, strictly
speaking, Mendelian disorders. There-
fore, although Mendelian disorders might
be individually rare exceptions (albeit
collectively numerous), ‘‘non-Mendelian
monogenic disorders’’ might be much
more common, individually and collec-
tively, and perhaps closer to the rule988 Immunity 42, June 16, 2015 ª2015 Elsevthan exceptions. The present study points
to the importance of such disorders in
autoimmunity. Of course, not all autoim-
mune patients carry monogenic lesions:
autoimmunity could be digenic, with two
loci of equal weight, or perhaps even tri-
genic. It could be somatic too, as illus-
trated by the impact of somatic FAS
mutations (Magerus-Chatinet et al.,
2011). Overall, recent breakthroughs in
monogenic autoimmunity remind us of
the heuristic importance of a key
Darwinian concept, referred to in biology
as population thinking by Ernst Mayr and
in medicine as chemical individuality by
Archibald Garrod: all living organisms
are unique (Casanova et al., 2014). There
are only patients, each being unique—
diseases are words used by default
across patients, pending the discovery
of patient-specific pathogenesis.
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Mouse bonemarrow cells cultured with GM-CSF are often used to generate dendritic cells (DCs); in this issue
of Immunity, Helft et al. (2015) show that this classical method produces heterogeneous populations of
myeloid cells that are only distantly related to macrophages and DCs found in vivo.In mice, dendritic cells (DCs) and mono-
cytes are continually replenished from
common DC precursors (CDPs) and
common monocyte precursors (cMoPs)
that are found in the bone marrow (BM).
In contrast, many macrophages (Macs)
develop from embryonic precursors thatseed body tissues before birth and then
self-maintain throughout adulthood (Varol
et al., 2015). Cells that resemble DCs or
Macs can also develop under steady-
state conditions from Ly6Chi monocytes
and have been called monocyte-derived
DCs and Macs, respectively, a processthat is enhanced under inflammatory con-
ditions (Bain et al., 2014; Tamoutounour
et al., 2013). Recent studies based on
ontogeny and global gene expression
profiles showed that CDP-derived DCs
can be organized into two main subsets
denoted as cDC1s and cDC2s (Guilliams
Figure 1. Dendritic Cells and Macrophages from GM-CSF-Supplemented Bone Marrow
Cell Cultures Are Distantly Related to In Vivo Dendritic Cells and Macrophages
Upper panel shows a schematic representation of the chemotaxis assay performed by Helft et al. (2015).
Their analysis of GM-CSF-supplemented bone-marrow cell cultures focused on GM-DCs and GM-Macs
that distantly resemble in vivo cDC2s and in vivo monocyte-derived cells, respectively. The chemotaxis
assay revealed that in response to the CCR7 ligand, CCL21, the CDP-derived GM-DCs but not the mono-
cyte-derived GM-Macs were capable of migrating toward CCL21. Lower panel shows possible alignment
of the cell types analyzed in vitro by Helft et al. (2015) with the myeloid cell types found in vivo. The lung is
taken as example. Upon inflammation induced by a microbial insult, cDC1s and cDC2s convey microbial
antigen to the draining lymph nodes and convert naive T cells into effector T (Teff) cells. In contrast, mono-
cyte-derived cells are thought to primarily remain in the inflamed lung parenchyma where they orchestrate
local immune responses, including the elicitation of lung-tropic effector T cells.
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Previewset al., 2014). cDC1s—also known as
CD8a+ or CD103+ DCs—express the
chemokine receptor XCR1 and excel in
the cross-presentation of cell-associated
antigens to CD8+ T cells whereas cDC2s
express high amounts of CD11b and are
functionally biased toward the activation
of CD4+ T cells. DCs are distributed
throughout tissues and secondary
lymphoid organs. Their rarity and time-
consuming extraction have led to the
development of culture systems in
which BM-resident precursors are differ-entiated into DCs under the influence
of the granulocyte-macrophage colony-
stimulating factor (GM-CSF) and further
enriched based on the expression of
CD11c (Inaba et al., 1992). The resulting
cells, called BM-derived DCs, have
been used in numerous studies. Con-
cerns, however, have been raised
regarding their exact identity and on the
possibility of aligning them with in vivo
DC subsets.
In this issue of Immunity, Helft et al.
(2015) demonstrate that culturing BMImmunitycells with GM-CSF produces a highly
heterogeneousmix of cells. Basedon their
hematopoietic origin and surface pheno-
type, the CD11c+MHCII+ cells arising in
such cultures are comprised of (1) cMoP-
derived cells that they termed GM-
Macs and defined as CD11c+MHCIIint
CD115(M-CSFR)+MerTK+ and (2) CDP-
derived cells that they termed GM-DCs
and defined as CD11c+MHCIIhiCD115–
CD135(Flt3)+ cells. Note that GM-
CSF-supplemented BM cultures also
contained large numbers of poorly char-
acterized CD11c+MHCII+ cells that lack
expression of CD115 and CD135. GM-
Macs were immotile, had a typical Mac
morphology, produced high amounts of
inflammatory mediators (IL-6, TNF-a,
CXCL1, CCL3, CCL5, and IL-12-IL-
23p40) in response to microbial stimuli,
and migrated in chemotaxis assay in
response to the CCR2 ligand, CCL2.
In contrast, GM-DCs were motile and
continuously emitted dendritic processes.
They produced low amounts of inflam-
matory cytokines and chemokines in
response to microbial stimuli and
migrated in response to the CCR7 ligand,
CCL21. In addition, GM-DCs showed a
superior T cell priming capacity as
compared to GM-Macs. Therefore, the
heterogeneity observed among CD11c+
BM-derived cells reflects the presence
of different myeloid cell subsets rather
the presence of a single DC subset at
distinct maturation stages.
Helft et al. (2015) used transcriptomic
analysis to assess whether GM-DCs and
GM-Macs have in vivo counterparts.
They showed that GM-DCs relate neither
to the XCR1+ cDC1s nor to the CD11b+
cDC2s found in vivo (Figure 1). GM-DCs,
however, appeared closer to in vivo
CD11b+ cDC2s in that their development
depends on IRF4 and because they
express CD11b and CD172a (SIRPa).
Likewise, on the basis of global gene
expression profile, GM-Macs did not
cluster with any of the Mac populations
documented in the Immgen database or
with the monocyte-derived DCs and
Macs found in the skin dermis (Tamou-
tounour et al., 2013). The observation
that GM-Macs can not be aligned with
any of the Mac subsets that are found
in vivo is consistent with the view that
the functional identity of Macs and, to a
certain extent of DCs, results from both
developmental and environmental cues42, June 16, 2015 ª2015 Elsevier Inc. 989
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Previews(Varol et al., 2015). The plasticity that is
manifested by the precursors of tissue
Macs and monocyte-derived cells that
emerge from the BM allow them to
adapt their terminal differentiation pro-
gram to the tissue in which they perma-
nently reside. Along that line, the culture
medium supplemented with GM-CSF
and fetal calf serum might in fact have
induced unique gene expression signa-
tures in the precursors of GM-Macs and
GM-DCs.
Although the field has moved forward
and largely focuses on in vivo and
ex vivo DCs and Macs, BM-derived DCs
and Macs are still the object of many
studies. The results of Helft et al. (2015)
are timely in that they stress that the
results of many in vitro studies need to
be treated with caution. For instance, a
recent study highlighting the power of
single-cell RNA sequencing in the iden-
tification of regulatory circuits molding
myeloid cell differentiation focused on
the response to lipopolysaccharide (LPS)
of cells present in GM-CSF-supple-
mented BM cultures and found that
hundreds of key immune genes were
bimodally expressed across cells (Shalek
et al., 2013). Reinterpretation of those
results in the light of the study of Helft
et al. (2015) showed that such bimodal
pattern of expression reflects the different
responses of GM-DCs and GM-Macs
to LPS rather than the existence of
stochastic mechanisms acting within a
homogeneous DC population and result-
ing in the activation of distinct functional
programs.
Numerous vaccination trials intending
to induce potent anti-tumoral responses
have been developed in humans using
cells that were differentiated in vitro from
blood monocytes using GM-CSF and
interleukin-4. Despite several implemen-990 Immunity 42, June 16, 2015 ª2015 Elsevtations aiming at loading such mono-
cyte-derived cells with tumor-associated
antigen and at activating them in vitro,
most of the injected monocyte-derived
cells remained at the site of injection and
did not reach the draining lymph nodes,
resulting in no survival benefits in vacci-
nated patients (Wimmers et al., 2014). It
is likely that the maturation program un-
folding in such in-vitro-grown heteroge-
neous monocyte-derived cells does not
closely match the one conferring unique
immunostimulatory andmigratory proper-
ties to in vivo CDP-derived DCs. Consis-
tent with that view, Helft et al. (2015)
showed that intravenous vaccination of
mice with CDP-derived GM-DCs pulsed
with OVA peptide protected mice from
subsequent challenge with OVA-express-
ing B16.F10 melanoma cells. In contrast,
10-fold higher numbers of monocyte-
derived GM-Macs were required to elicit
the same degree of anti-tumor protection.
If these findings are transposable to hu-
mans, natural precursors of DCs should
thus constitute a far better starting mate-
rial for the manufacturing of cell-based
vaccines than monocytes. Interestingly,
two recent reports pave the way to such
achievements in that they not only identi-
fied the direct precursors of the human
counterpart of cDC1s and cDC2s, but
also described an in vitro culture system,
allowing differentiation of all major types
of human DCs from BM and cord-blood-
derived CD34+ hematopoietic stem and
progenitor cells (Breton et al., 2015; Lee
et al., 2015). Finally, the results of Helft
et al. (2015) suggest that in-vitro-grown
myeloid cells can be conditioned by the
cocktail of goodies contained in the
culture medium. Further refinement of
culture conditions should thus permit the
manufacture of a` la carte CDP-derived
human DCs with immunostimulatoryier Inc.functions mimicking those of DCs
that have matured in vivo. Therefore
those cells, rather than GM-CSF-induced
monocyte-derived cells, will probably
constitute the best candidates for the
design of successful next-generation
DC-based vaccines.REFERENCES
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